Remicade's approval for ulcerative colitis raises questions about new high-tech versus older approaches

November 2005

Remicade's approval for ulcerative colitis raises questions about new high-tech versus older approaches.

Over 500,000 Americans try various drugs for ulcerative colitis. About 85% of patients with severe disease end up with a colectomy when the drugs don't work.

But this is changing.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote